

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT6729802

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
SHENGWEI LI	04/12/2019
DIXIANG LUO	04/11/2019
YIRAN WU	04/12/2019
MING ZHOU	04/12/2019
LIANG HUA	04/12/2019
PENGYI LUO	04/12/2019
YANG WANG	04/12/2019
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	GENEKEY BIOTECH (CHENGDU) CO., LTD.
<b>Street Address:</b>	4-301 HAITE INTERNATIONAL PLAZA
<b>Internal Address:</b>	1 S. KEYUAN RD. GAOXIN DISTRICT
<b>City:</b>	CHENGDU
<b>State/Country:</b>	CHINA
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
<b>Application Number:</b>	17327494
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(202)842-7899
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	617 937-2348
<b>Email:</b>	lromano@cooley.com
<b>Correspondent Name:</b>	JESSICA D. CANDE
<b>Address Line 1:</b>	COOLEY, LLP
<b>Address Line 2:</b>	1299 PENNSYLVANIA AVENUE NW
<b>Address Line 4:</b>	WASHINGTON, D.C. 20004
<b>ATTORNEY DOCKET NUMBER:</b>	SBTI-001/C01US
<b>NAME OF SUBMITTER:</b>	JESSICA D. CANDE
<b>SIGNATURE:</b>	/Jessica D. Cande/
<b>DATE SIGNED:</b>	05/26/2021

PATENT

**Total Attachments: 11**

source=SBTI-001C01US-Assignment Genekey Biotech (Chengdu) Co., Ltd#page1.tif

source=SBTI-001C01US-Assignment Genekey Biotech (Chengdu) Co., Ltd#page2.tif

source=SBTI-001C01US-Assignment Genekey Biotech (Chengdu) Co., Ltd#page3.tif

source=SBTI-001C01US-Assignment Genekey Biotech (Chengdu) Co., Ltd#page4.tif

source=SBTI-001C01US-Assignment Genekey Biotech (Chengdu) Co., Ltd#page5.tif

source=SBTI-001C01US-Assignment Genekey Biotech (Chengdu) Co., Ltd#page6.tif

source=SBTI-001C01US-Assignment Genekey Biotech (Chengdu) Co., Ltd#page7.tif

source=SBTI-001C01US-Assignment Genekey Biotech (Chengdu) Co., Ltd#page8.tif

source=SBTI-001C01US-Assignment Genekey Biotech (Chengdu) Co., Ltd#page9.tif

source=SBTI-001C01US-Assignment Genekey Biotech (Chengdu) Co., Ltd#page10.tif

source=SBTI-001C01US-Assignment Genekey Biotech (Chengdu) Co., Ltd#page11.tif

ASSIGNMENT

SHENGWEI LI, DIXIANG LUO, YIRAN WU, MING ZHOU, LIANG HUA, PENGYI LUO and YANG WANG (each referred to as "Assignor") have made an invention (the "Invention") set forth in an application for patent entitled **HUMAN NEUREGULIN-1 (NRG-1) RECOMBINANT FUSION PROTEIN COMPOSITIONS AND METHODS OF USE THEREOF**, and which is a:

- (1)  provisional application  
(a)  to be filed herewith; or  
(b)  bearing Application No. , and filed on ;
- (2)  non-provisional application  
(a)  to be filed herewith; or  
(b)  bearing Application No. 16/381,206,  
and filed on April 11, 2019; and
- (3)  PCT application  
(a)  bearing Application No. PCT/US2019/026889,  
and filed on April 11, 2019

WHEREAS, Genekey Biotech (Chengdu) Co., Ltd., having its principal place of business at 4-301 Haite International Plaza, 1 S. Keyuan Rd. Gaoxin District, Chengdu SC China, its successors, legal representatives and assigns, (the "Assignee"), is desirous of acquiring the entire right, title, and interest in: the Invention(s); the application(s) for patent identified above; the right to file applications for patent of the United States or other countries on the Invention(s); any application(s) for patent of the United States or other countries claiming priority to, and/or the benefit of, these applications; any provisional or other right to recover any and all past, present, and future damages, including royalties, for any and all past, present, and future infringements of these application(s); and any and all patent(s) of the United States or other countries that may be granted therefor or thereon.

NOW, THEREFORE, for good and sufficient consideration, the receipt of which is hereby acknowledged, and to the extent that the Assignor has not done so already via a prior agreement with the Assignee or a predecessor in interest of the Assignee, or if the Assignor has already done so via a prior agreement with the Assignee or a predecessor in interest of the Assignee then in confirmation of any obligation to do so in said prior agreement, the Assignor has sold, assigned, transferred, and set over, and by these presents does sell, assign, transfer, and set over, unto the Assignee, its successors, legal representatives, and assigns, the Assignor's entire right, title, and interest in:

(a) the Invention(s);

(b) the application(s) for patent identified above;

(c) the right to file applications for patent of the United States or other countries on the Invention(s), including all rights under the Hague Convention, the Paris Convention for the Protection of Industrial Property, and under the Patent Cooperation Treaty, and all rights of claiming priority in any country of the world;

(d) any application(s) for patent of the United States or other countries claiming the Invention(s);

(e) any application(s) for patent of the United States or other countries claiming priority to, and/or the benefit of, at least one of the application(s) for patent identified above or any application(s) for patent claiming the Invention(s), including any priority application(s), substitute application(s), division(s), continuation(s), and continuation(s)-in-part;

(f) any provisional or other right to recover any and all past, present, and future damages, including royalties, for any and all past, present, and future infringements of any application for patent identified in the preceding paragraphs (b)-(e) and of any and all patent(s) granted based thereon in the United States and in all other countries; and

(g) any patent(s) of the United States or other countries that may be granted for or on any application for patent identified in the preceding paragraphs (b)-(e), including any reissue(s), reexamination(s), revival(s), renewal(s) and extension(s) of said patent(s).

The above-granted rights, titles, and interests are to be held and enjoyed by the Assignee, for its own use and behalf and the use and behalf of its successors, legal representatives, and assigns, as fully and entirely as the same would have been held and enjoyed by the Assignor had this sale and assignment not been made.

The Assignor hereby represents to the Assignee, its successors, legal representatives, and assigns, that, at the time of execution and delivery of these presents, or if applicable, at such time said prior agreement was executed, the Assignor is a lawful owner of an undivided interest in the entire right, title, and interest in and to the Invention(s), that the Invention(s) are unencumbered, except, if applicable, by obligation to assign in accordance with said prior agreement, and that the Assignor has good and full right and lawful authority to sell and convey the same in the manner set forth herein, and that Assignor will not make or enter into any assignment, sale, agreement or encumbrance which would conflict with these presents.

The Assignor hereby covenants and agrees to and with the Assignee, its successors, legal representatives, and assigns, that the Assignor will sign all papers and documents, take all lawful oaths, and do all acts necessary or required to be done in connection with

Attorney Docket No. SBTL-001/001US (332030-2004)

any and all proceedings for the procurement, maintenance, enforcement and defense of the Invention(s), said application(s), and said patent(s), including interference and derivation proceedings, and any post-grant proceedings (e.g., opposition proceedings, post-grant reviews, *Inter partes* reviews, supplemental examinations, etc.) without charge to the Assignee, its successors, legal representatives, and assigns, but at the cost and expense of the Assignee, its successors, legal representatives, and assigns.

The Assignor hereby authorizes and requests the attorneys of COOLEY LLP to insert in the spaces provided above the filing date, the application number, and the attorney docket number of the application(s) identified above when known.

The Assignor hereby requests the Commissioner of Patents to issue said patents of the United States to the Assignee for the sole use and behalf of the Assignee, its successors, legal representatives, and assigns.

Date: April 12, 2019 By: Shengwei Li  
SHENGWEI LI

Witness Signature: Yang Xu Date: April 12, 2019

Print Witness Name: YANG XU

Witness Signature: YAN GAO Date: 4/11/2019

Print Witness Name: YAN GAO

Date: 04/11/2019 By: DIXIANG LUO  
DIXIANG LUO

Witness Signature: Yang Xu Date: 04/18/2019

Print Witness Name: YANG XU

Witness Signature: YAN GAO Date: 04/11/2019

Print Witness Name: YAN GAO

Date: April. 12. 2019. By: Yiran Wu.  
YIRAN WU

Witness Signature: Yang Xu Date: April. 12. 2019

Print Witness Name: YANG XU

Witness Signature: YAN GAO Date: 4/12/2019

Print Witness Name: YAN GAO



Date: April. 12. 2019 By: Ming Zhou  
MING ZHOU

Witness Signature: Yang Xu Date: April. 12. 2019

Print Witness Name: YANG XU

Witness Signature: YAN GAO Date: 4/12/2019

Print Witness Name: YAN GAO

Date: April. 12 - 2019 By: LIANG HUA  
LIANG HUA

Witness Signature: Yang Xu Date: April. 12. 2019

Print Witness Name: YANG XU

Witness Signature: YAN GAO Date: 4/12/2019

Print Witness Name: YAN GAO

Date: April 12, 2019 By: PENGYILUO  
PENGYI LUO

Witness Signature: Yang Xu Date: April 12, 2019  
Print Witness Name: YANG XU

Witness Signature: YAN GAO Date: 4/12/2019  
Print Witness Name: YAN GAO

Date: DATE: April 12, 2019

By: YANG WANG  
YANG WANG

Witness Signature: Yang Xu

Date: April 12, 2019

Print Witness Name: YANG XU

Witness Signature: YAN GAO

Date: 4/12/2019

Print Witness Name: YANG GAO

For and on behalf of ASSIGNEE:

Date: Apr. 12, 2019 By: Bin Zhao  
Name: **BIN ZHAO**  
Title: General Manager  
Company: Genekey Biotech (Chengdu) Co., Ltd.

Witness Signature: Yang Xu Date: Apr. 12, 2019  
Print Witness Name: **YANG XU**

Witness Signature: YAN GAO Date: 4/12/2019  
Print Witness Name: **YAN GAO**